Top Evidence-Based Interventions to Lower Biological Age

Epigenetic aging clocks estimate biological age based on DNA molecular tagging patterns, and interventions like semaglutide and ketamine reduce these estimates in humans.

(The principal investigator behind the review on interventions that influence biological age, Dr. David Sinclair | The Society of the Four Arts)

As reviewed in this article, epigenetic aging clocks have estimated the effects of pharmaceutical interventions, lifestyle habits, supplements, and clinical interventions on biological age.

Aging &amp; Longevity

Participants: Sedentary older adults 
Dosage: 6 mg/week of rapamycin

In older adults, the FDA-approved drug rapamycin, associated with prolonging lifespan, blunts improvements in physical performance.

Skin &amp; Muscle

Model: C57BL/6 mice
Dosage: 500 mg/kg/day of SRN-901 via oral gavage for six days per week starting at 18 months of age; 14.4 ppm of rapamycin mixed in food starting at 18 months of age; 300 mg/kg/day of NMN via oral gavage for six days per week starting at 18 months of age; and 300 mg/kg/day of NR via oral gavage for six days per week starting at 18 months of age

Seragon Publishes Record-Breaking SRN-901 Longevity Data, Demonstrating 33% Lifespan Extension in Mice

In a newly published mouse study, SRN-901 extended remaining lifespan by 33%, slowed frailty progression, and lowered tumor incidence.

Seragon’s SRN-901 extended the remaining lifespan of adult mice by 33%, attenuated frailty progression by 70%, and reduced tumor incidence by 30.53%, according to a newly published preclinical study.

Joe Rogan’s Top Supplements for 2026

Joe Rogan’s latest supplement stack includes compounds targeting longevity, cognition, immunity, fitness, and optimal hormone levels.

(Joe Rogan on set for his podcast | Spotify Newsroom)

Joe Rogan’s updated supplement stack for 2026 includes compounds targeting longevity, cognition, immunity, fitness, and optimal hormone levels.

Approved Human Study Sets Up Pivotal Test for Aging Theory from Harvard’s David Sinclair

In a major proving ground test for the longevity field, the FDA has given its approval for a human trial for a gene therapy attempting a near-total rejuvenating reset of cells.

(David Sinclair, Michael Ringel, Sharon Rosenzweig-Lipson, and Jerry McLaughlin of Life Biosciences | Longevity.technology)

The FDA has greenlighted Life Biosciences’ first human trial testing whether their gene therapy can confer a near-total rejuvenating reset of cells.

Search Result: epigenetic age

Top Evidence-Based Interventions to Lower Biological Age

Rapamycin and Exercise: New Study Finds Potential Performance Decline

Seragon Publishes Record-Breaking SRN-901 Longevity Data, Demonstrating 33% Lifespan Extension in Mice

Joe Rogan’s Top Supplements for 2026

FDA Greenlights Life Biosciences’ Human Study, Setting Up Pivotal Test for Aging Theory from Harvard’s David Sinclair